Cargando…
Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19
Autores principales: | Kow, Chia Siang, Aldeyab, Mamoon, Hasan, Syed Shahzad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532950/ https://www.ncbi.nlm.nih.gov/pubmed/33011825 http://dx.doi.org/10.1007/s00228-020-03008-6 |
Ejemplares similares
-
Use of sulforaphane in COVID-19: Clinical trials are needed
por: Kow, Chia Siang, et al.
Publicado: (2022) -
Metformin in COVID-19: clinical trials are needed to prove its benefits
por: Kow, Chia Siang, et al.
Publicado: (2022) -
Antimicrobial consumption among hospitalized patients with COVID-19 in Pakistan
por: Ul Mustafa, Zia, et al.
Publicado: (2021) -
Azithromycin in patients with COVID-19: Friend or foe?
por: Kow, Chia Siang, et al.
Publicado: (2021) -
Pharmacologic therapeutic options for thromboprophylaxis in COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)